Navigation Links
Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
Date:6/9/2008

sts.

Other adverse events commonly observed with SYMLIN when co-administered with insulin were mostly gastrointestinal in nature, including nausea, which was the most frequently reported adverse event. The incidence of nausea was higher at the beginning of SYMLIN treatment and decreased with time in most patients. The incidence and severity of nausea are reduced when SYMLIN is gradually increased to the recommended doses.

About Diabetes

Diabetes affects over 20 million Americans and is growing at three times the rate of population growth.(1) Approximately 4.5 million patients with diabetes use insulin. Diabetes is the fifth leading cause of death by disease in the United States.(1) Diabetes is a complex metabolic disease manifesting with a defect in the beta cells in the pancreas, resulting in a deficiency of both insulin and amylin secretion.(2) Poor control of blood sugar may result in severe long-term complications such as kidney failure, nerve damage, blindness, amputation and cardiovascular disease.(1)

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
5. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
6. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
10. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
11. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... and SHANGHAI , Sept. 22, ... a global knowledge leader in healthcare technology, media ... support healthcare innovation in China ... health technologies. Continua and BHG announced this new ... held this week in Washington, DC ...
(Date:9/22/2014)... 2014 Persistence Market Research ( ... Study on Ophthalmic Devices: Asia ... market was valued at USD 29,171.5 million in 2014 and ... from 2014 to 2020, to reach an estimated value ... the full Global Market Study on Ophthalmic Devices:  Asia ...
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
Breaking Medicine Technology:Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
... SILVER SPRING, Md., March 25, 2011 The U.S. Food ... patients with late-stage (metastatic) melanoma, the most dangerous type ... ) Melanoma is the leading cause ... cases of melanoma were diagnosed in the United States ...
... CoreLab Partners, Inc , the global entity resulting ... is set to attend and actively participate in several ... two weeks. "The legacy of our organization ... physicians, scientists and operational personnel have provided to the ...
Cached Medicine Technology:FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 2FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 3CoreLab Partners Collaborates at Worldwide Industry Conferences 2
(Date:9/22/2014)... 22, 2014 Oregon Governor John ... as “Oregon Chiropractic Health and Wellness Month.” , ... (UWS) celebrates 110 years of leadership in educating ... was the first educational institution offering a doctor ... expanded over the past 110 years and now ...
(Date:9/22/2014)... Don Allred Insurance is pleased to announce the ... The satellite office, located in the Holly Hill Mall on ... and offer all of the same professional services as the ... spokesperson Scott Allred cites an expanding client base and the ... the major factors driving the decision to open a new ...
(Date:9/22/2014)... Austin, Texas (PRWEB) September 22, 2014 Join ... hosts the 1st Annual “Denim & Pearls Casino Night” Gala. ... Pok-E-Jo’s, door prizes, professional casino games, a raffle, and live ... The gala will feature a special buy-in for a ... , The funds from this event will be used ...
(Date:9/22/2014)... IsoComforter, Inc., one of the Nation’s premier ... of an innovative IsoTube technology and uniflow technology that ... ridges provide optimal contact and pain control. By utilizing ... fluid reservoir to a pad that is applied to ... continuous cold therapy for an extended period of time ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 ... care market occupies a significant presence in the ... most widespread healthcare problems globally. Key factors underlying ... lifestyle habits such as smoking; increasing levels of ... and expanding base of aging population vulnerable to ...
Breaking Medicine News(10 mins):Health News:Oregon Governor Proclaims October as “Chiropractic Month” – UWS Brought Chiropractic Health Care to Oregon in 1904 2Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Maverick’s Miracle Babies Foundation Presents the Denim & Pearls Casino Night September 26, 2014 2Health News:IsoComforter Cold Therapy Introduces Innovative IsoTube Technology 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 4
... could lead to new treatments, researchers say , , WEDNESDAY, ... immune cells exhausted from fighting HIV infection has been ... that a molecule called Tim-3 is present at high ... combating HIV, the virus that causes AIDS. Blocking the ...
... physicians and caregivers to improve cultural sensitivity and ... these women to get mammograms that could save ... the Journal of General Internal Medicine. ... perceive they are being treated with disrespect and ...
... Latest Release Includes Enhanced Scheduling, Financial and ... Social Workers, GREAT RIVER, N.Y., Nov. ... of enterprise-wide software and services for health ... availability,release of version 7.5 of Helper, the ...
... bring enough benefit to offset expense , , WEDNESDAY, Nov. ... may not justify the marginal benefit, a new study ... (AHA) annual scientific sessions in New Orleans found that ... in some patients but "at a cost generally considered ...
... Demonstrate Best Strategic Use of Mergers ... ... http://www.thedeal.com ) magazine has named Abbott,( http://www.abbott.com )as the healthcare sector ... Abbott for the,most effective strategic use of acquisitions and divestitures., ...
... of Rutgers University is one of 10 2008 Pew ... Pew Charitable Trusts. Launched in 1991, the Pew Latin ... trained Latin American scientists who show potential for stimulating ... as well as fostering collaboration between scientists in Latin ...
Cached Medicine News:Health News:Way to Rescue Tired Immune Cells Fighting HIV Found 2Health News:Fear, misconceptions about screenings keep many African-Americans from getting mammograms 2Health News:Fear, misconceptions about screenings keep many African-Americans from getting mammograms 3Health News:Netsmart Technologies Releases Version 7.5 of Helper(TM) Practice Management Software 2Health News:Netsmart Technologies Releases Version 7.5 of Helper(TM) Practice Management Software 3Health News:Angioplasty Not Always Worth the Price 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 3
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Medicine Products: